159 filings
Page 7 of 8
8-K
gwuw7yv7p d9
8 Nov 18
Results of Operations and Financial Condition
4:35pm
8-K
xjm96i1
1 Nov 18
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
6:08am
8-K
rhsoit
9 Aug 18
Denali Therapeutics Reports Second Quarter 2018 Financial Results
12:00am
8-K
y3ikc32nguna 3p
1 Aug 18
Denali Therapeutics Announces Positive Clinical Results from LRRK2 Inhibitor Program for Parkinson’s Disease
4:38pm
CT ORDER
rkcf4 7nc9yiup
17 Jul 18
Confidential treatment order
12:00am
10-K/A
k3ilyycuyrxo4qs
13 Jul 18
Annual report (amended)
5:01pm
8-K
gihetp8t5in3kx
15 Jun 18
Submission of Matters to a Vote of Security Holders
4:22pm
8-K
7lk9doh4
30 May 18
Denali Therapeutics Announces Early Exercise of Its Option to Acquire F-star Gamma
4:36pm
10-Q
jhqn3mesz6y7p5x
11 May 18
Quarterly report
8:07am
8-K
vqtyg8y82hcoznd07l5
11 May 18
Denali Therapeutics Reports First Quarter 2018 Financial Results
8:01am
8-K
8cul1ozt3 j0j02qk
7 May 18
Entry into a Material Definitive Agreement
4:31pm
DEFA14A
74y3au4qz x20jc
26 Apr 18
Additional proxy soliciting materials
4:30pm
DEF 14A
j3804b
26 Apr 18
Definitive proxy
4:26pm
8-K
b2v2hd0rw38ldi
19 Mar 18
Results of Operations and Financial Condition
12:00am
10-K
kxh1n3t
19 Mar 18
Annual report
12:00am
8-K
1dh1q1a cu
5 Jan 18
Entry into a Material Definitive Agreement
12:00am
8-K
z1aidgt vv38c6d2e2
12 Dec 17
Denali Therapeutics Announces Closing of Initial Public Offering, Including Full
12:00am
S-8
12x wznk2oxm0zx
8 Dec 17
Registration of securities for employees
12:00am